EP Patent

EP3037547A1 — New fusion gene detected in lung cancer

Assigned to National Center for Global Health and Medicine · Expires 2016-06-29 · 10y expired

What this patent protects

A method for detecting a gene fusion serving as a responsible mutation (driver mutation) for cancer, the method comprising the step of detecting any one of an EZR-ERBB4 fusion polynucleotide, a KIAA1468-RET fusion polynucleotide, a TRIM24-BRAF fusion polynucleotide, a CD74-NRG1 f…

USPTO Abstract

A method for detecting a gene fusion serving as a responsible mutation (driver mutation) for cancer, the method comprising the step of detecting any one of an EZR-ERBB4 fusion polynucleotide, a KIAA1468-RET fusion polynucleotide, a TRIM24-BRAF fusion polynucleotide, a CD74-NRG1 fusion polynucleotide, and an SLC3A2-NRG1 fusion polynucleotide, or a polypeptide encoded thereby, in an isolated sample from a subject with cancer.

Drugs covered by this patent

Patent Metadata

Patent number
EP3037547A1
Jurisdiction
EP
Classification
—
Expires
2016-06-29
Drug substance claim
No
Drug product claim
No
Assignee
National Center for Global Health and Medicine
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.